Skip to main
CNTB

CNTB Stock Forecast & Price Target

CNTB Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Connect Biopharma Hldgs is well-positioned for success with in-depth partnerships, promising trial results, and a large potential market for their medication. Key factors such as upcoming tests and potential FDA acceptance will determine the future success of the medication in the market. Disciplined financial planning and partnerships have also given the company a strong foundation for growth and potential commercialization of their medication.

Bears say

Connect Biopharma Hldgs is a high-risk investment due to its heavy reliance on a small clinical dataset, third-party manufacturing, and other typical risks associated with a single-asset clinical-stage biotech company. The company's main revenue driver, its rademikibart drug, is largely unproven and still in clinical trials for treatment of asthma and COPD exacerbations. Additionally, there is uncertainty surrounding the company's ability to finance its Phase 3 program without diluting shares. Overall, these factors contribute to a negative outlook on Connect Biopharma Hldgs' stock.

CNTB has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Connect Biopharma Holdings (CNTB) Forecast

Analysts have given CNTB a Strong Buy based on their latest research and market trends.

According to 7 analysts, CNTB has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Connect Biopharma Holdings (CNTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.